
Ovid Therapeutics (OVID) Stock Forecast & Price Target
Ovid Therapeutics (OVID) Analyst Ratings
Bulls say
Ovid Therapeutics is expected to have strong long-term performance with the potential for multi-billion dollar market opportunities due to their differentiated pipeline targeting seizures and epilepsy. Their most advanced program, OV329, has demonstrated a favorable safety profile and strong cortical inhibition activity, putting it on track for potential approval and launch with a predicted long-term return on investment.
Bears say
Ovid Therapeutics is facing a number of challenges that could negatively impact their stock. The company is in the early stages of development and relies heavily on external funding, which could result in delays or termination of development campaigns. In addition, the company's therapeutic candidates, including OV350 and OV4071, have not yet been proven in the market and will face tough competition from established drugs. The upcoming KCC2 R&D event may provide some insight, but with a potential peak revenue of only $6B, Ovid's stock may not have significant growth potential in the near future.
This aggregate rating is based on analysts' research of Ovid Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Ovid Therapeutics (OVID) Analyst Forecast & Price Prediction
Start investing in Ovid Therapeutics (OVID)
Order type
Buy in
Order amount
Est. shares
0 shares